Russian government takes steps to prevent further drug price increases

5 January 2015
moscow-big

The Russian government is designing a number of measures aimed at preventing a further increase of drug prices in the domestic market, reports The Pharma Letter's local correspondent.

According to Russia’s Prime Minister Dmitry Medvedev, the current situation in the market remains complex, which is reflected by the ever-increasing drug prices, caused by currency fluctuations and other factors. Mr Medvedev has also said that the situation is aggravated by the ever growing prices for domestic drugs.

At the same time, according to Olga Golodets, Russia’s deputy Prime Minister, the government controls the current situation in the market, which is reflected by the fact that prices for essential drugs have increased by only 4% since the beginning of 2014.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics